The experiments produced evidence that patients will absorb more of the unnamed drug, tested in Phase I in clinical trials, when taken with "flat" or degassed Sprite.
Faraj Atassi and colleagues note that efforts are underway to develop more anticancer medications that patients can take by mouth. However, biological variations among patients - due to variations in stomach acidity and other factors - can reduce the effectiveness of oral anticancer drugs. Such was the case with the unnamed anticancer drug in the study, identified only as "Compound X." There were wide differences in how the drug was absorbed in the first patients who took it.
The scientists combined Compound X with Captisol, a substance that helps improve the solubility of drug ingredients, and turned to the artificial stomach. That glass-and-plastic device is used to study how drugs and foods dissolve through the GI tract. They showed that Sprite seemed to control stomach acidity in a way likely to allow greater absorption of the drug into the body.
Based on the results, the scientists suggest that patients in future clinical trials take the drug with Sprite.
The study has been published in ACS' Molecular Pharmaceutics, a bi-monthly journal.